CPT code 88173 covers cytopathology testing of fine needle aspirate specimens, combining technical laboratory processing and interpretation with result reporting. This code is important nationally because fine needle aspiration cytology is a common minimally invasive diagnostic tool across oncology, endocrinology, and other specialties; accurate coding ensures appropriate capture of laboratory work and clinical interpretation for patient management and payment. Key payers in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn: the clinical context and service components that CPT code 88173 represents; typical sites of service where this work is performed; common billing considerations and modifiers (listed separately); and areas where benchmarks or policy updates commonly affect coding and reimbursement. The summary provides a foundation for operational staff, laboratory managers, and billing professionals who need to align documentation and claims with the procedural steps of fine needle aspiration cytopathology. Data not available in the input for payer-specific rates, associated taxonomies, and ICD-10 mappings is noted and should be referenced from payer guidance or institutional billing resources.